Form 4 for FENC FENNEC PHARMACEUTICALS INC.
Accepted 2024-04-03 00:00:00 ET · period of report 2024-04-03 · accession 0001415889-24-010101 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-04-03 | 2024-04-03 | FENC | Raykov Rosty | CEO, Dir | S - Sale | $10.78 | -40.6K | 302.1K | -12% | -$437.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common shares | 2024-04-03 | S | D | 26,000 | $10.78 | 276,054 | D | — | — | (F2) Represents shares sold pursuant to a 10b5-1 plan dated December 14, 2023. |
| 2 | Common | Common shares | 2024-04-03 | S | D | 14,584 | $10.78 | 302,054 | D | — | — | (F1) Represents shares sold pursuant to a 10b5-1 plan dated December 14, 2023. Shares sold to satisy tax obligation. |